Long-term outcomes and effects of hypofractionated radiotherapy in microinvasive breast cancer: Analysis from a randomized trial
The Breast · 2023
DOI: 10.1016/j.breast.2023.02.005 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Breast, 2023. Verfasst von Mira Goldberg und 10 weiteren Autor:innen. Beteiligte Einrichtung: McMaster University, Hamilton, ON, Canada. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Canada Research Chairs Program.
Abstract (Originalsprache)
PURPOSE: The natural history of microinvasive (T1mi) breast cancer is uncertain. The objective was to evaluate long-term local and distant recurrence rates following breast conserving surgery (BCS) in a prospective cohort of patients with T1mi compared to T1a-2 disease who received whole breast irradiation (WBI) in the context of a randomized trial of hypofractionation. METHODS: 1234 patients with T1-2 N0 breast cancer were randomized to receive adjuvant WBI of 42.5Gy in 16 daily fractions, or 50Gy in 25 daily fractions after BCS. An analysis of patients with T1mi tumors compared with T1a-2 disease was performed. Kaplan-Meier estimates of local recurrence (LR), distant recurrence, and overall survival (OS) were compared using the log-rank test. RESULTS: Median follow-up was 12 years. T1mi was found in 3% (n = 38) of patients. The 10-year LR rate was 22.6% in T1mi vs. 6.9% in T1a-2 breast cancer [hazard ratio (HR) = 3.73; 95% confidence interval (CI): 1.93, 7.19; p < 0.001]. The 10-year risk of distant recurrence was 5.1% for T1mi, and 12.1% for T1a-2 disease (HR = 0.56; 95% CI: 0.19, 1.84; p = 0.36). Ten-year OS was 91.5% in T1mi and 84.4% in T1a-2 disease, (HR = 0.48; 95% CI: 0.18, 1.30; p = 0.14). Rates of LR did not differ whether treated by hypofractionation or conventional fractionation (HR = 1.21; 95% CI: 0.35, 4.18; p = 0.77). CONCLUSIONS: The risk of LR was considerably higher in patients with T1mi compared to T1a-2 tumors, but OS remained very good. Future research should evaluate the utility of wider local excision and boost radiation to optimize local control for microinvasive breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- McMaster University, Hamilton, ON, Canada.
- Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
- University of Ottawa, Ottawa, ON, Canada.
- Northeastern Ontario Regional Cancer Centre, Sudbury, ON, Canada.
- London Health Sciences Centre, London, ON, Canada.
- Princess Margaret Cancer Centre, Toronto, ON, Canada.
Förderung
- Canada Research Chairs Program
Zitieren
APA
Goldberg, M., Parpia, S., Rakovitch, E., Chang, L., Bowen, J., Lukka, H., Perera, F., Fyles, A., Wright, J., Sussman, J., & Whelan, T. (2023). Long-term outcomes and effects of hypofractionated radiotherapy in microinvasive breast cancer: Analysis from a randomized trial. The Breast. https://doi.org/10.1016/j.breast.2023.02.005
Vancouver
Goldberg M, Parpia S, Rakovitch E, Chang L, Bowen J, Lukka H, et al. Long-term outcomes and effects of hypofractionated radiotherapy in microinvasive breast cancer: Analysis from a randomized trial. The Breast. 2023. doi:10.1016/j.breast.2023.02.005
BibTeX
@article{Goldberg2023,
author = {Goldberg, Mira and Parpia, Sameer and Rakovitch, Eileen and Chang, Lynn and Bowen, Julie and Lukka, Himanshu and Perera, Francisco and Fyles, Anthony and Wright, James and Sussman, Jonathan and Whelan, Timothy},
title = {Long-term outcomes and effects of hypofractionated radiotherapy in microinvasive breast cancer: Analysis from a randomized trial},
journal = {The Breast},
year = {2023},
doi = {10.1016/j.breast.2023.02.005}
}
EUVIMED